Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 2Head & Neck 1CNS 1

Conditions

Head and Neck Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Salivary Gland Neoplasms 2Rectal Neoplasms 1Esthesioneuroblastoma, Olfactory 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 7Cetuximab 5selpercatinib 3cemiplimab 3Trastuzumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Erlotinib Hydrochloride 3Bortezomib 3sargramostim 2motexafin gadolinium 2entinostat 2Specimen Handling 2Radiotherapy 2Oxaliplatin 2Irinotecan 2Fluorodeoxyglucose F18 2Drug Therapy 2Docetaxel 2Biopsy 2ulixertinib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1tipifarnib 1tanespimycin 1spartalizumab 1serabelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Immunologic Techniques × Head & Neck × Clear all
NCT00896896 2013-04-02

Immunoreactivity to Cetuximab in Cancer Patients

Vanderbilt-Ingram Cancer Center

Completed
538 enrolled
CNSGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Head and Neck Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Colorectal Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡